Mersana Therapeutics reports third quarter 2025 financial results
I'm PortAI, I can summarize articles.
Mersana Therapeutics Inc. reported a net loss of $7.5 million for Q3 2025, an improvement from a $11.5 million loss in Q3 2024. General and administrative expenses decreased to $6.3 million from $9.9 million. Cash and equivalents totaled $56.4 million as of September 30, 2025. The company will be acquired by Day One Biopharmaceuticals Inc., with the deal closing expected by January 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments